Merlin

MPH, of Brigham & Women's Hospital at Harvard Medical School and lead investigator of the MERLIN-TIMI 36 study.

Research Funding: CV Therapeutics (acquired by Gilead Pharmaceuticals) provided research grant support for the MERLIN-TIMI 36 trial.

The Company believes that the increase in GSIS seen with ranolazine may contribute to the statistically significant reductions in hemoglobin A1c (HbA1c) levels observed with Ranexa in cardiovascular patients with diabetes from the phase 3 CARISA (n=189 with angina and diabetes) and MERLIN-TIMI 36 (n=2,220 with acute coronary syndromes and diabetes) clinical trials.

Effects of Ranolazine on Disease-Specific Health Status and Quality of Life: Results from the MERLIN-TIMI 36 Randomized Trial; Poster, Monday, March 31, 2008, 3:00 p.

A clinical trial update session entitled, The Effect of Ranolazine, a Novel Anti-anginal Agent with Electrophysiologic Properties, on the Incidence of Tachyarrhythmias: Results from the MERLIN-TIMI 36 Randomized Controlled Trial, is scheduled for presentation Wednesday, September 5 at 9:45 a.

The new medicine, Ranexa, approved last year for patients not responding to traditional therapy, was studied in the 6500 patient MERLIN-TIMI 36 trial and found to be a safe and effective anti-anginal and anti-ischemic therapy.

We are extremely pleased to have reached a significant landmark for this important clinical trial and appreciate the hard work of all of the MERLIN-TIMI 36 investigators and research coordinators worldwide," said Eugene Braunwald, M.